- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Hope Rugo: Talking With Other Prescribers About Biosimilars
Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, disucusses the conversations she is having and expects to have with fellow prescribers about biosimilars in oncology.
Transcript:
Are other breast cancer specialists looking forward to Mylan’s biosimilar trastuzumab coming to market? Are you getting questions from physicians about the biosimilar?
We haven’t really seen questions in the [United States] about biosimilars yet. I think there’s a lot of interest in understanding what a biosimilar is, [and] how the different trials have looked at biosimilars because there are many, many now out there, all looking for regulatory approval in addition to the drugs that are already approved in the [United States] and Europe.
But, I think that, because there’s a lot of experience with biosimilars in rheumatologic disease, there is a greater appreciation for the importance of biosimilars in oncology.
I think once the drugs are available, there’s going to be a big need for education and understanding of where these drugs should be and how comfortable people feel with them. But right now, I think in the United States because we can’t use them yet, that the main interest has been in supportive care and in rheumatologic disease.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
